Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study

Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019

(2020) Irene Galani et al.   Eurosurveillance

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis

(2020) Marco Fiore et al.   Antibiotics-Basel

Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens

(2019) Ilias Karaiskos et al.   Expert Opinion on Drug Metabolism & Toxicology

Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam

(2019) Galani Irene et al.   CLINICAL MICROBIOLOGY AND INFECTION

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

(2019) Ilias Karaiskos et al.   Frontiers in Public Health

EFFICACY OF CEFTAZIDIME-AVIBACTAM IN MONOTHERAPY OR COMBINATION THERAPY AGAINST CARBAPENEM RESISTANT GRAM NEGATIVE ORGANISMS: A META-ANALYSIS

(2019) Lorenzo Onorato et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization

(2019) P. Gaibani et al.   CLINICAL MICROBIOLOGY AND INFECTION

Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients

(2019) Vasiliki Tsolaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections

(2019) Sarah C J Jorgensen et al.   Open Forum Infectious Diseases

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

(2018) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae

(2018) Mario Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program, 2012 to 2015

(2018) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016

(2018) Irene Galani et al.   Eurosurveillance

Combining VITEK® 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility

(2018) J. Lellouche et al.   CLINICAL MICROBIOLOGY AND INFECTION

CLINICAL CHARACTERISTICS AND PROGNOSIS OF INFECTIONS CAUSED BY OXA-48 CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE IN PATIENTS TREATED WITH CEFTAZIDIME-AVIBACTAM

(2018) C. De la Calle et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Combination therapy for extensively-drug resistant gram-negative bacteria

(2017) Ilias Karaiskos et al.   Expert Review of Anti-Infective Therapy

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

(2017) Belén Gutiérrez-Gutiérrez et al.   LANCET INFECTIOUS DISEASES

Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms: a case series from the compassionate-use program

(2016) Elizabeth Temkin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

(2016) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

(2016) Mervyn Singer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Carbapenemase-producingEnterobacteriaceaein Europe: assessment by national experts from 38 countries, May 2015

(2015) Barbara Albiger et al.   Eurosurveillance

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

(2015) David P. Nicolau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study

(2015) Mario Tumbarello et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control

(2015) T. Tängdén et al.   JOURNAL OF INTERNAL MEDICINE

Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems

(2014) George L. Daikos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treating infections caused by carbapenemase-producing Enterobacteriaceae

(2014) L.S. Tzouvelekis et al.   CLINICAL MICROBIOLOGY AND INFECTION

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

(2013) L Silvia Munoz-Price et al.   LANCET INFECTIOUS DISEASES

CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting

(2008) Teresa C. Horan et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES